TP53 wild-type

News alerts, weekly reports and conference planners

Entrez ID:

7157

Related biomarkers:

‹

›

TP53 wild-type	Endometrial Cancer	TP53 wild-type	Endometrial Cancer	selinexor Sensitive: B - Late Trials Karyopharm Press Release - 3 weeks (New B) selinexor Sensitive : B Karyopharm Press Release - 3wk	selinexor Sensitive: B - Late Trials Karyopharm Press Release - 3 weeks selinexor Sensitive : B Karyopharm Press Release - 3 weeks - (New B)
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	PCR Sensitive: A2 - Guideline PCR Sensitive : A2	PCR Sensitive: A2 - Guideline PCR Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	FCR Sensitive: A2 - Guideline FCR Sensitive : A2	FCR Sensitive: A2 - Guideline FCR Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	chlorambucil Sensitive: A2 - Guideline chlorambucil Sensitive : A2	chlorambucil Sensitive: A2 - Guideline chlorambucil Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	venetoclax + obinutuzumab Sensitive: A2 - Guideline venetoclax + obinutuzumab Sensitive : A2	venetoclax + obinutuzumab Sensitive: A2 - Guideline venetoclax + obinutuzumab Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	CD20 inhibitor Sensitive: A2 - Guideline CD20 inhibitor Sensitive : A2	CD20 inhibitor Sensitive: A2 - Guideline CD20 inhibitor Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2	obinutuzumab + acalabrutinib Sensitive: A2 - Guideline obinutuzumab + acalabrutinib Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	ibrutinib + obinutuzumab Sensitive: A2 - Guideline ibrutinib + obinutuzumab Sensitive : A2	ibrutinib + obinutuzumab Sensitive: A2 - Guideline ibrutinib + obinutuzumab Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	ibrutinib + rituximab Sensitive: A2 - Guideline ibrutinib + rituximab Sensitive : A2	ibrutinib + rituximab Sensitive: A2 - Guideline ibrutinib + rituximab Sensitive : A2
TP53 wild-type	Chronic Lymphocytic Leukemia	TP53 wild-type	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 wild-type	Chronic Lymphocytic Leukemia	TP53 wild-type	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
TP53 wild-type	Acute Myelogenous Leukemia	TP53 wild-type	Acute Myelogenous Leukemia	RG7388 Resistant: B - Late Trials RG7388 Resistant : B	RG7388 Resistant: B - Late Trials RG7388 Resistant : B
TP53 wild-type	Lymphoma	TP53 wild-type	Lymphoma	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	KRT-232 Sensitive: C2 – Inclusion Criteria KRT-232 Sensitive : C2	KRT-232 Sensitive: C2 – Inclusion Criteria KRT-232 Sensitive : C2
TP53 wild-type	Estrogen Receptor Positive Breast Cancer	TP53 wild-type	Estrogen Receptor Positive Breast Cancer	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	BI 907828 Sensitive: C2 – Inclusion Criteria BI 907828 Sensitive : C2	BI 907828 Sensitive: C2 – Inclusion Criteria BI 907828 Sensitive : C2
TP53 wild-type	Acute Myelogenous Leukemia	TP53 wild-type	Acute Myelogenous Leukemia	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3
TP53 wild-type	Liposarcoma	TP53 wild-type	Liposarcoma	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3	MK-8242 Sensitive: C3 – Early Trials MK-8242 Sensitive : C3
TP53 wild-type	Multiple Myeloma	TP53 wild-type	Multiple Myeloma	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3
TP53 wild-type	Liposarcoma	TP53 wild-type	Liposarcoma	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3	HDM201 Sensitive: C3 – Early Trials HDM201 Sensitive : C3
TP53 wild-type	Merkel Cell Carcinoma	TP53 wild-type	Merkel Cell Carcinoma	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3
TP53 wild-type	Melanoma	TP53 wild-type	Melanoma	trametinib + dabrafenib + KRT-232 Sensitive: C3 – Early Trials trametinib + dabrafenib + KRT-232 Sensitive : C3	trametinib + dabrafenib + KRT-232 Sensitive: C3 – Early Trials trametinib + dabrafenib + KRT-232 Sensitive : C3
TP53 wild-type	Acute Myelogenous Leukemia	TP53 wild-type	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
TP53 wild-type	Myelodysplastic Syndrome	TP53 wild-type	Myelodysplastic Syndrome	GS-4721 Sensitive: C3 – Early Trials GS-4721 Sensitive : C3	GS-4721 Sensitive: C3 – Early Trials GS-4721 Sensitive : C3
TP53 wild-type	Salivary Gland Cancer	TP53 wild-type	Salivary Gland Cancer	APG-115 Sensitive: C3 – Early Trials APG-115 Sensitive : C3	APG-115 Sensitive: C3 – Early Trials APG-115 Sensitive : C3
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3

TP53 wild-type

Associations